Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission

Area of Science:

• Proteomics
• Biomarker Discovery
• Immunology

Background:

• Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) necessitates intensive immunosuppression.
• Prolonged therapy post-remission poses risks due to lack of reliable remission biomarkers.
• Current markers like C-reactive protein and ANCA titer are insufficient for precise remission assessment.

Purpose of the Study:

• To identify reliable plasma proteomic biomarkers for disease remission in AAV patients.
• To develop and validate a protein signature for clinical decision-making in AAV management.

Main Methods:

• A two-tiered proteomics strategy combining global discovery and targeted validation was employed.
• A 7-protein panel was identified and implemented in a targeted mass spectrometry assay.
• Diagnostic performance was validated in an independent patient cohort, adjusting for confounders.

Main Results:

• A distinct 7-protein signature indicative of AAV remission was identified.
• The 7-protein panel demonstrated superior diagnostic performance compared to C-reactive protein and ANCA titer.
• The assay showed consistent performance in an independent validation cohort.

Conclusions:

• The 7-protein panel serves as a promising biomarker for AAV remission.
• This biomarker panel has the potential to optimize immunosuppressive therapy, reduce toxicity, and lower healthcare expenditures.
• The proteomics approach offers a scalable model for biomarker discovery in complex inflammatory diseases.